Aequus Boosts Supply Amid Bimatoprost Shortage
Company Announcements

Aequus Boosts Supply Amid Bimatoprost Shortage

Aequus Pharmaceuticals (TSE:AQS) has released an update.

Aequus Pharmaceuticals has ramped up the supply of its Zimed® PF 0.03% bimatoprost eye drops to address the Canadian shortage and ensure continuous patient access to this essential glaucoma treatment. Zimed® PF, which is preservative-free and offered in a multi-dose format, is currently the only option for 0.03% bimatoprost, leading to an expected increase in demand and sales for Aequus. The company’s commitment to addressing the shortage aligns with its focus on developing and commercializing high-quality, differentiated pharmaceutical products.

For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Strong Q2 Financials
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Celebrates Zimed® PF Sales Record
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App